Pfizer

Ligand Receives Milestone Payment from Merck

Retrieved on: 
Wednesday, January 13, 2021
Biotechnology, FDA, Infectious diseases, Health, Pharmaceutical, Health sciences, Companies, Pharmaceutical sciences, Pharmacy, CAC 40, Sanofi, Pharmaceutical industry, Pfizer, Protein Expression Technology Platform, Ligand Pharmaceuticals

This collaboration with Merck is one of the core assets that catalyzed our acquisition of Pfenex last October, said John Higgins, Chief Executive Officer of Ligand.

Key Points: 
  • This collaboration with Merck is one of the core assets that catalyzed our acquisition of Pfenex last October, said John Higgins, Chief Executive Officer of Ligand.
  • Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
  • Ligands business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering.
  • Ligand has established multiple alliances, licenses and other business relationships with the worlds leading pharmaceutical companies including Amgen, Merck, Pfizer, Roche, Sanofi, Janssen, Takeda, Gilead Sciences, GSK and Baxter International.

Former Pfizer Director of Worldwide Regulatory and Safety Operations Information Management - Reporting and Dictionaries, John (Doug) Sydow, Appointed Senior Advisor at Nextrove, LLC

Retrieved on: 
Tuesday, January 12, 2021
Health sciences, Health, Pharmaceuticals policy, Clinical research, Health care quality, Pharmacovigilance, Pfizer, Pharmaceutical industry

Doug joins with nearly 30 years' experience in the pharmaceutical domain, most recently serving as Director, Worldwide Regulatory and Safety OperationsInformation Management, Reporting and Dictionaries at Pfizer.

Key Points: 
  • Doug joins with nearly 30 years' experience in the pharmaceutical domain, most recently serving as Director, Worldwide Regulatory and Safety OperationsInformation Management, Reporting and Dictionaries at Pfizer.
  • "Nextrove is uniquely positioned to focus on multiple facets of pharmaceutical and biotech," said Doug.
  • Spending most of his career at Pfizer, Inc., from locations in Bridgewater, NJ and Collegeville, PA, Doug was most recently Director, Worldwide Regulatory and Safety OperationsInformation Management - Reporting and Dictionaries.
  • Throughout his tenure, Doug was responsible for global planning and budgeting for all pharmacovigilance systems, safety database implementations and upgrades, change management, custom reporting, global regulatory reporting, and risk management.

Moderna, Pfizer Climb Apex Clearing’s ‘Millennial 100’ Rankings as Investors Shift Focus to COVID-19 Recovery

Retrieved on: 
Tuesday, January 12, 2021
Professional services, Finance, Articles, Medical research, Health sciences, Demographics, Millennials, Life sciences, Moderna, Pfizer

Apex Clearing, the custody and clearing engine powering the future of wealth management, released its Q4 2020 Apex Millennial 100 report, an analysis of the top 100 stocks owned by millennial investors using Apex partner applications as of December 31, 2020.

Key Points: 
  • Apex Clearing, the custody and clearing engine powering the future of wealth management, released its Q4 2020 Apex Millennial 100 report, an analysis of the top 100 stocks owned by millennial investors using Apex partner applications as of December 31, 2020.
  • Millennial investors caught the financial services industrys attention in 2020, said Bill Capuzzi, CEO of Apex Clearing.
  • Themes in the Q4 Apex Millennial 100 include:
    Vaccines are millennials next COVID-19 bet: Across generations, vaccine names rose in the rankings.
  • Moderna (#27) rose 11 spots in the Millennial 100 while Pfizer (#20) rose 39 spots as investors repositioned their portfolios for 2021.

Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative

Retrieved on: 
Tuesday, January 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Companies, Pfizer, Life sciences, Health sciences, Medical research

Pfizer Inc. (NYSE: PFE) today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI).
  • Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizers scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest to Pfizer.
  • $25 million in Cambridge, Mass.-based Trillium Therapeutics (Nasdaq: TRIL), a clinical-stage immuno-oncology company focused on developing innovative therapies for the treatment of cancer.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.

Retrieved on: 
Tuesday, January 12, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Pfizer, Companies, PureTech Health, Life sciences, Economy of the United States, VE202, Vedanta Biosciences, PureTech Health

PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative .

Key Points: 
  • PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative .
  • As part of the investment, Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, will join Vedantas Scientific Advisory Board.
  • Vedanta will retain control of all its programs and has granted Pfizer a right of first negotiation on VE202.
  • Vedanta will retain control of all its programs and has granted Pfizer a right of first negotiation on VE202.

Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.

Retrieved on: 
Tuesday, January 12, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Articles, Branches of biology, Philosophy, Microbiomes, Bacteriology, Environmental microbiology, Microbiology, Microbiome, Vedanta, Pfizer, Human microbiome, VE202, Vedanta Biosciences

Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative .

Key Points: 
  • Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative .
  • We thank Pfizer for its investment in Vedanta and support of our IBD program and look forward to advancing microbiome modulation as a potential new treatment modality for IBD patients, said Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of Vedanta Biosciences.
  • Vedanta will retain control of all its programs and has granted Pfizer a right of first negotiation on VE202.
  • Vedanta Biosciences is leading the development of a potential new category of oral therapies based on rationally defined consortia of bacteria derived from the human microbiome.

Press release - COVID-19 vaccines: Public Health Committee MEPs to quiz Commission

Retrieved on: 
Monday, January 11, 2021
Medical research, Health sciences, Medicine, Health, COVID-19 vaccine, BioNTech, Pfizer, Moderna, Vaccine, Tozinameran, The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations

At the Plenary session in December 2020, Parliament expressed support for speedy authorisation of safe vaccines.

Key Points: 
  • At the Plenary session in December 2020, Parliament expressed support for speedy authorisation of safe vaccines.
  • The Commission has since given conditional marketing authorisation for two COVID-19 vaccines, one developed by BioNTech and Pfizer and one by Moderna Biotech Spain, S.L.
  • You can follow the committee meeting live here from 9 am on Tuesday 12 January.
  • On 22 September 2020, Parliament held a public hearing on How to secure access to COVID-19 vaccines for EU citizens: clinical trials, production and distribution challenges.

Combination Products 2021 Virtual Seminar: Documentation Requirements and Interfacing - ResearchAndMarkets.com

Retrieved on: 
Monday, January 11, 2021
Health, Biotechnology, Economy, Madison, New Jersey, Pfizer, Wyeth, Market data, Regulatory affairs, Marketplace, Krems, Pharmaceutical companies, Human activities

Previously, Michor worked for Chiesi-Torrex, Wyeth Whitehall Export Croma Pharma GmbH.

Key Points: 
  • Previously, Michor worked for Chiesi-Torrex, Wyeth Whitehall Export Croma Pharma GmbH.
  • She teaches regulatory affairs and clinical strategies at the University of Krems, Austria, and is an independent expert to the European Commission.
  • ResearchAndMarkets.com is the world's leading source for international market research reports and market data.
  • We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

MacroGenics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, January 11, 2021
American Enterprise Institute, Pfizer, Scott Gottlieb, Trademark, Gottlieb, Marketing, Business, Market economics)

A corporate overview provided by MacroGenics management will be available for on-demand viewing from January 11 - 14, 2021.

Key Points: 
  • A corporate overview provided by MacroGenics management will be available for on-demand viewing from January 11 - 14, 2021.
  • In addition, MacroGenics President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a panel discussion on Precision Medicine hosted by Scott Gottlieb, M.D., Former Commissioner of the U.S. Food and Drug Administration.
  • MacroGenics management will participate in one-on-one meetings and provide a corporate overview onJanuary 14, 2021 at 10:00 AM ET.
  • MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Global Active Pharmaceutical Ingredient (API) Market Analysis 2020 with Company Profiles of Leading Players Including Roche Holding AG, Pfizer Inc, Merck & Co. and More

Retrieved on: 
Monday, January 11, 2021
Articles, Life sciences, Companies, Pharmaceutical industry, Pharmacology, Pharmacy, Teva Pharmaceuticals, Novartis, Pfizer, Merck & Co., Bristol Myers Squibb, Outsourcing

The global API market is forecasted to reach US$270.83 billion in 2024, growing at a CAGR of 6.5% for the period spanning 2020-2024.

Key Points: 
  • The global API market is forecasted to reach US$270.83 billion in 2024, growing at a CAGR of 6.5% for the period spanning 2020-2024.
  • The factors such as increasing ageing population, rising healthcare expenditure per capita, growing cancer patients, inclining orphan drugs industry and accelerating outsourcing of API drugs are expected to drive the market.
  • The report provides a comprehensive analysis of the global API market, segmented by synthesis (biological & small molecule) and manufacturers (captive & merchant).
  • The competitive landscape of the market, along with the company profiles of leading players (Roche Holding AG, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Limited) are also presented in detail.